Adalimumab therapy in hepatitis B virus-negative polyarteritis nodosa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Polyarteritis nodosa (PAN) is a difficult-to-treat rheumatology disorder, and biologic agents have been used in such patients with a treatment failure or the disease relapse. Case presentation: We report a 42-year-old male Han Chinese who received adalimumab (ADA) alone during his vasculitis relapse, manifesting with weight loss, ankle arthritis, testicular inflammation and new-onset hypertension. Under the ADA 40mg biweekly subcutaneous injection, there were the disappearance of clinical activity and no disease flares with a follow-up period of 26 months. Conclusion: The clinical observation in this patient suggests a potential efficacy of ADA therapy in controlling the disease activity of PAN.

Original languageEnglish
Article numbere11053
JournalMedicine (United States)
Volume97
Issue number25
DOIs
Publication statusPublished - 2018 Jun 1

Fingerprint

Polyarteritis Nodosa
Hepatitis B virus
Recurrence
Biological Factors
Rheumatology
Subcutaneous Injections
Vasculitis
Treatment Failure
Ankle
Arthritis
Weight Loss
Therapeutics
Observation
Hypertension
Inflammation
Adalimumab

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{6d431d8fdc3140459f132161388b847c,
title = "Adalimumab therapy in hepatitis B virus-negative polyarteritis nodosa",
abstract = "Introduction: Polyarteritis nodosa (PAN) is a difficult-to-treat rheumatology disorder, and biologic agents have been used in such patients with a treatment failure or the disease relapse. Case presentation: We report a 42-year-old male Han Chinese who received adalimumab (ADA) alone during his vasculitis relapse, manifesting with weight loss, ankle arthritis, testicular inflammation and new-onset hypertension. Under the ADA 40mg biweekly subcutaneous injection, there were the disappearance of clinical activity and no disease flares with a follow-up period of 26 months. Conclusion: The clinical observation in this patient suggests a potential efficacy of ADA therapy in controlling the disease activity of PAN.",
author = "Wang, {Chrong Reen} and Yang, {Chao Chun}",
year = "2018",
month = "6",
day = "1",
doi = "10.1097/MD.0000000000011053",
language = "English",
volume = "97",
journal = "Medicine (United States)",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "25",

}

Adalimumab therapy in hepatitis B virus-negative polyarteritis nodosa. / Wang, Chrong Reen; Yang, Chao Chun.

In: Medicine (United States), Vol. 97, No. 25, e11053, 01.06.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adalimumab therapy in hepatitis B virus-negative polyarteritis nodosa

AU - Wang, Chrong Reen

AU - Yang, Chao Chun

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Introduction: Polyarteritis nodosa (PAN) is a difficult-to-treat rheumatology disorder, and biologic agents have been used in such patients with a treatment failure or the disease relapse. Case presentation: We report a 42-year-old male Han Chinese who received adalimumab (ADA) alone during his vasculitis relapse, manifesting with weight loss, ankle arthritis, testicular inflammation and new-onset hypertension. Under the ADA 40mg biweekly subcutaneous injection, there were the disappearance of clinical activity and no disease flares with a follow-up period of 26 months. Conclusion: The clinical observation in this patient suggests a potential efficacy of ADA therapy in controlling the disease activity of PAN.

AB - Introduction: Polyarteritis nodosa (PAN) is a difficult-to-treat rheumatology disorder, and biologic agents have been used in such patients with a treatment failure or the disease relapse. Case presentation: We report a 42-year-old male Han Chinese who received adalimumab (ADA) alone during his vasculitis relapse, manifesting with weight loss, ankle arthritis, testicular inflammation and new-onset hypertension. Under the ADA 40mg biweekly subcutaneous injection, there were the disappearance of clinical activity and no disease flares with a follow-up period of 26 months. Conclusion: The clinical observation in this patient suggests a potential efficacy of ADA therapy in controlling the disease activity of PAN.

UR - http://www.scopus.com/inward/record.url?scp=85049252722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049252722&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000011053

DO - 10.1097/MD.0000000000011053

M3 - Article

C2 - 29923995

AN - SCOPUS:85049252722

VL - 97

JO - Medicine (United States)

JF - Medicine (United States)

SN - 0025-7974

IS - 25

M1 - e11053

ER -